Hi hetty, OSUR does look to have significant progress in China ("ongoing talks with distributor in China"). They said the same thing last quarter already and there is no regulatory activity at all by OSUR (my knowledge at least). I'm not concerned because they are not competitive price-wise in China.
It is clear that OSUR is predominantly targeting the European Union now and other industrialized countries Singapur Korea, ... but this is not Calypte's market which focuses on countries where HIV infections are much more frequent. The reason for OSUR's strategy is probably the price.
The only thing noteworthy: OSUR said yesterday they are close to sign a distributor for Oraquick in the Middle East. So the price will decide in this region one day.
Hettygreen, I think all of us were surprised by the OTC oral product announcement in the UAE. I suspect there will be more "positive" announcements to come. News that will be anticipated i.e. China, and events that will be new. I've been in this for what I consider a long time and I have to keep telling myself to be patient.
News 
Market Data 
Discover 
